NCT04581382 - Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 14, 2020

Primary Completion Date

October 6, 2024

Study Completion Date

October 6, 2024

Conditions

Melanoma

Interventions

BIOLOGICAL

Nivolumab

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

RADIATION

Radiation Therapy

Undergo radiation therapy

BIOLOGICAL

Therapeutic Exchange Plasma

Undergo therapeutic plasma exchange

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Positron Emission Tomography

Undergo PET

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Trial Locations (1)

Mayo Clinic in Rochester, Rochester